Status:
TERMINATED
Colombia Epidemiologic Surveillance Study
Lead Sponsor:
Pfizer
Conditions:
Pneumonia
Meningitis
Eligibility:
All Genders
28-36 years
Brief Summary
The study will determine the reduction in invasive pneumococcal disease (IPD) after the introduction of a National Immunization Program with PCV-7 in Bogota. The original LEAP study determine incidenc...
Detailed Description
The study was stopped based on a decision to include PCV 10 in the National Immunization Program in Colombia. The study was designed to measure the impact of PCV 7 and 13 and is no longer feasible.
Eligibility Criteria
Inclusion
- Children 28 days to 36 months of age
- Presenting to a participating facility with a measured temperature of 39 degrees C or higher within 24 hours prior to screening, or with clinical suspicion of pneumonia, meningitis, bacteremia, sepsis, or other invasive pneumococcal disease
Exclusion
- Any patient hat based on the clinical impression of the treating physician should not participate in the study: examples such as those with suspected dengue or urinary tract infection
Key Trial Info
Start Date :
September 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
32867 Patients enrolled
Trial Details
Trial ID
NCT00428051
Start Date
September 1 2006
End Date
October 1 2011
Last Update
October 27 2011
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Goiânia, Goiás, Brazil, 074065-050
2
Pfizer Investigational Site
Bogotá, Colombia
3
Pfizer Investigational Site
Uruca, Provincia de San José, Costa Rica, 607-1159